Shots: Sandoz will hold IPR of Humira in certain countries and will also pay royalties to AbbVie. In response AbbVie will not make any payments to Sandoz Humira’s license period […]readmore
Tags : AbbVie
Shots: The approval is based on two P-III studies assessing Orilissa 150 mg qd and 200 mg bid vs PBO enrolling 1,700 women with moderate to severe endometriosis pain P-III […]readmore
Biosimilars
Biotech
Regulatory
Mylan Receives EU Marketing Approval for Adalimumab Biosimilar “Hulio”
Shots: Hulio’s EU Marketing Approval is followed after CHMP approval that demonstrated analytical, functional, clinical and immunogenicity data similar to AbbVie’s Humira In 2018, Kyowa and Mylan signed an agreement […]readmore
Shots: Combination of Imbruvica (ibrutinib) & Rituxan (rituximab) approval is the first and only CT free combination treatment in all line of therapies This approval is based on P-III iNNOVATE […]readmore
Shots: AbbVie will obtain a worldwide, exclusive license to develop and commercialize ARGX-115-based products Argenx to receive development, regulatory and commercial milestone payments of up to $625M, and has rights […]readmore